Core Insights - The article emphasizes the importance of investing in quality companies at reasonable valuations, inspired by renowned investors like Warren Buffett, Peter Lynch, and Terry Smith [1]. Group 1 - The focus is on long-term fundamentals driving share prices, with an emphasis on predicting earnings per share [1].

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $13.1 million, up from $12.6 million a year ago, and full year revenue of $41.8 million, a 71% increase from $24.4 million in 2023 [9][24][27] - Net income for Q4 2024 was $1.5 million or $0.09 per diluted share, compared to $4.2 million or $0.26 per diluted share a year ago [26] - Adjusted EBITDA for 2024 was $8.7 million compared to $0.3 million in 2023, indicating significant improvement [29] Business Line Data and Key Metrics Changes - The company achieved a quarterly record of 39 SRT-100 systems shipped in Q4 and 115 for the full year, increases of 18% and 74% respectively [10] - Gross profit for Q4 was $7.1 million, or 54.4% of revenues, down from 62.3% in the prior year due to a one-time discount and higher service costs [24] Market Data and Key Metrics Changes - The company noted that five systems were shipped to international customers in Q4 and ten for the full year, indicating a focus on expanding international sales [11] - The Fair Deal Agreement program has gained traction, particularly among large dermatology groups and private equity-backed practices [8][14] Company Strategy and Development Direction - The company is focusing on expanding its Fair Deal Agreement program, which allows practices to acquire SRT systems without significant upfront costs, thus enhancing customer relationships and driving recurring revenue [15][16] - The company is exploring new markets, including veterinary medicine, which demonstrates the versatility of its SRT technology [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for 2025, particularly from the Fair Deal Agreement program, which is expected to contribute meaningfully to revenue in the second half of the year [14][36] - The company is preparing to resubmit its TBI-510K application in the first half of 2025, aiming to diversify its product line and solidify its market position [22] Other Important Information - The company ended 2024 with $22.1 million in cash and cash equivalents, with no debt, reflecting a strong capital position [12][29] - The company anticipates that first quarter 2025 sales could be considerably lower than the first quarter of 2024 due to seasonal factors [32] Q&A Session Summary Question: How many units shipped in Q4 were part of the Fair Deal Agreement? - The number of units shipped in Q4 was 39, none of which were part of the Fair Deal Agreement [44] Question: What percentage of new customers are inclined to sign up for the Fair Deal Agreement? - Management indicated that many customers are deciding between purchasing and the Fair Deal Agreement, suggesting a strategic shift towards the latter for long-term benefits [46] Question: Are there any new competitors emerging in the space? - Management noted that the main competitor remains Mohs surgery, and there have been no significant new entrants or dropouts in the market [60] Question: What percent of sales came from the largest customer? - Of the 39 units delivered, 25 came from the largest customer, and they are expected to continue purchasing throughout the year [66] Question: Can you provide more color on the interest from private equity groups? - There are between 12 and 15 major private equity-backed roll-ups, representing about 20% of dermatology clinics, and interest in the Fair Deal Agreement is growing among these groups [70]

Core Insights - Sensus Healthcare, Inc. reported quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share, and down from $0.26 per share a year ago, representing an earnings surprise of -10% [1] - The company posted revenues of $13.07 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 32.59%, compared to year-ago revenues of $12.57 million [2] - Sensus Healthcare shares have increased approximately 22% since the beginning of the year, outperforming the S&P 500's gain of 2.7% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $11.46 million, and for the current fiscal year, it is $0.71 on revenues of $49.34 million [7] - The estimate revisions trend for Sensus Healthcare is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Sensus Healthcare belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Nevro, is expected to report a quarterly loss of $0.79 per share, reflecting a year-over-year change of -426.7%, with revenues projected at $105.65 million, down 9.1% from the previous year [9]

Financial Performance - Revenues for Q4 2024 were $13.1 million, up 4% from $12.6 million in Q4 2023, and full-year revenues reached $41.8 million, a 71% increase from $24.4 million in 2023[5][12] - Net income for Q4 2024 was $1.5 million, or $0.09 per diluted share, marking the fifth consecutive quarter of profitability, compared to $4.2 million, or $0.26 per diluted share, in Q4 2023[9][16] - Gross profit for Q4 2024 was $7.1 million, or 54.4% of revenues, down from $7.8 million, or 62.3% of revenues, in Q4 2023, primarily due to a one-time discount and higher service costs[7] - Adjusted EBITDA for Q4 2024 was $1.9 million, down from $5.7 million in Q4 2023, reflecting higher income tax expense in the prior year[10] - Gross profit for the year 2024 was $24,431,000, a significant increase from $14,060,000 in 2023, representing a growth of 73%[30] - Net income for Q4 2024 was $1,546,000, compared to $4,210,000 in Q4 2023, indicating a decrease of 63%[30] - Operating expenses for Q4 2024 totaled $5,381,000, significantly higher than $2,244,000 in Q4 2023, an increase of 140%[30] - The company reported a basic net income per share of $0.09 for Q4 2024, down from $0.26 in Q4 2023[30] Assets and Liabilities - Cash and cash equivalents at year-end 2024 were $22.1 million, with no debt, compared to $23.1 million in 2023[11] - Total current assets rose to $56,738,000 in 2024, up from $49,528,000 in 2023, reflecting an increase of 15%[31] - Accounts receivable increased significantly to $19,731,000 in 2024, compared to $10,645,000 in 2023, marking an increase of 85%[31] - Total liabilities increased to $6,338,000 in 2024 from $4,868,000 in 2023, representing a rise of 30%[31] - Retained earnings grew to $13,434,000 in 2024, up from $6,787,000 in 2023, indicating a growth of 98%[31] - Cash and cash equivalents decreased to $22,056,000 in 2024 from $23,148,000 in 2023, a decline of 5%[31] Product and Market Developments - A record 39 SRT systems were shipped in Q4 2024, representing an 18% increase year-over-year, with a total of 115 systems shipped for the year, up 74%[5][12] - The company plans to re-submit its TDI 510(k) application in the first half of 2025, indicating ongoing product innovation efforts[3] - The Fair Deal Agreement program is expected to contribute to revenues in the second half of 2025, with multiple new agreements in the pipeline[2] - The company anticipates that Q1 2025 sales could be considerably lower than Q1 2024, but expects full-year sales growth in 2025 compared to 2024[4] Research and Development - Research and development expenses for 2024 were $4.2 million, an increase of $0.5 million from 2023, driven by higher compensation and product development costs[15]

Company Performance - Sensus Healthcare, Inc. (SRTS) closed at $6.92, reflecting a +1.91% change from the previous day's close, outperforming the S&P 500's daily gain of 0.92% [1] - Over the past month, shares of the company have decreased by 5.3%, while the Medical sector gained 3.83% and the S&P 500 gained 0.81% [1] Upcoming Earnings - The company's earnings report is scheduled for February 5, 2025, with an expected EPS of $0.10, indicating a 61.54% decline from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projected at $9.86 million, down 21.6% from the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Sensus Healthcare, Inc. are important for investors, as positive revisions can indicate a favorable business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides a functional rating system for assessing stock performance [4] Zacks Rank and Valuation - Sensus Healthcare, Inc. currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining steady over the past month [5] - The company is trading at a Forward P/E ratio of 9.56, which is a discount compared to the industry average Forward P/E of 28.24 [6] Industry Context - The Medical - Instruments industry, to which Sensus Healthcare belongs, has a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [6][7] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, indicating that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [7]

Company Performance - Sensus Healthcare reported third-quarter 2024 earnings of 7 cents per share, exceeding the Zacks Consensus Estimate of a loss of 2 cents per share by 450% [1] - The company's third-quarter revenue surpassed estimates by 51.3% [1] - Sensus Healthcare shares ended the last trading session 7.9% higher at $7.34, following an impressive trading volume [4] Stock Trends - The stock has experienced a 20.9% loss over the past four weeks prior to the recent increase [4] - The consensus EPS estimate for Sensus Healthcare has remained unchanged over the last 30 days, indicating a potential for future price movements [6] Industry Context - Sensus Healthcare operates within the Zacks Medical - Instruments industry [7] - Another company in the same industry, DexCom, closed the last trading session 0.4% higher at $80.57, with a 2.7% return over the past month [7]

Core Viewpoint - Sensus Healthcare, Inc. (SRTS) has shown a significant price increase of 31% over the past four weeks, with analysts projecting a mean price target of $11.67, indicating a potential upside of 36% from the current price of $8.58 [1] Price Target Analysis - The average price target for SRTS ranges from a low of $10 to a high of $14, with a standard deviation of $2.08, suggesting a variability in estimates. The lowest estimate indicates a 16.6% increase, while the highest suggests a 63.2% upside [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [7] Earnings Estimates and Analyst Sentiment - Analysts have shown growing optimism regarding SRTS's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [9] - The Zacks Consensus Estimate for the current year has increased by 13.9% over the past month, with two estimates rising and no negative revisions [10] - SRTS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside [11] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions. Analysts may set overly optimistic targets due to business incentives [5][6][8]

Financial Performance - Revenues for Q3 2024 were $8.8 million, a 127% increase from $3.9 million in Q3 2023, driven by higher superficial radiotherapy unit sales[2] - Net income for Q3 2024 was $1.2 million, or $0.07 per diluted share, compared to a net loss of $1.5 million, or $0.09 per share, in Q3 2023[9] - Adjusted EBITDA for Q3 2024 was $1.6 million, compared to negative $1.7 million in Q3 2023[9] - Revenues for the nine months ended September 30, 2024, were $28.7 million, a 143% increase from $11.8 million in the same period of 2023[11] - Revenues for Q3 2024 reached $8,839,000, a significant increase from $3,898,000 in Q3 2023, representing a growth of 126%[26] - Net income for Q3 2024 was $1,215,000, a recovery from a net loss of $1,451,000 in Q3 2023[26] Cash and Assets - The company exited Q3 2024 with $22.6 million in cash and cash equivalents, with no debt[10] - Total current assets increased to $54,806,000 as of September 30, 2024, up from $49,528,000 at the end of 2023[27] - Accounts receivable, net, rose to $16,961,000 in Q3 2024, compared to $10,645,000 in Q3 2023, reflecting improved sales collection[27] - Retained earnings grew to $11,888,000 as of September 30, 2024, up from $6,787,000 at the end of 2023, indicating stronger profitability retention[28] Expenses and Liabilities - Operating expenses for Q3 2024 totaled $3,745,000, a decrease from $3,884,000 in Q3 2023, showing cost management efforts[26] - Research and development expenses for Q3 2024 were $0.9 million, down from $1.1 million in Q3 2023[8] - Total liabilities increased to $5,727,000 as of September 30, 2024, from $4,868,000 at the end of 2023[28] Sales and Market Expansion - A total of 27 systems were shipped in Q3 2024, including one SRT-100 unit to an international customer, compared to 11 systems in Q3 2023[2] - The company signed a Fair Deal Agreement with Platinum Dermatology Partners, expanding access to SRT for patients across 130 clinics in the U.S.[3] Profitability Metrics - Gross profit for Q3 2024 was $5.2 million, or 59.3% of revenues, compared to $2.0 million, or 51.0% of revenues, in Q3 2023[6] - Gross profit for Q3 2024 was $5,240,000, compared to $1,989,000 in Q3 2023, indicating a gross margin improvement[26] Other Financial Metrics - The company reported interest income of $279,000 in Q3 2024, slightly up from $277,000 in Q3 2023[26] - The weighted average number of shares used in computing net income per share was 16,321,131 for Q3 2024, compared to 16,270,403 for Q3 2023[26] Market Overview - The market for non-melanoma skin cancer treatments is significant, with an estimated 70 million Americans affected during their lifetime[4]

Core Viewpoint - The article emphasizes the importance of identifying and sustaining stock trends for successful short-term investing, highlighting the need for sound fundamentals and positive earnings estimates to maintain momentum [1]. Group 1: Stock Performance - Sensus Healthcare, Inc. (SRTS) has shown a solid price increase of 16.1% over the past 12 weeks, indicating investor confidence in its potential upside [3]. - The stock has also increased by 14.9% over the last four weeks, suggesting that the upward trend is still intact [4]. - SRTS is currently trading at 89.6% of its 52-week high-low range, indicating a potential breakout [4]. Group 2: Fundamental Strength - SRTS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting strong optimism from the brokerage community regarding its near-term price performance [6]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like SRTS that are on an upward trend supported by strong fundamentals [2]. - There are over 45 Zacks Premium Screens available for investors to find stocks that align with their personal investing styles [7].

Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 450%. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced earnings of $0.10, delivering a surprise of 233.33%.Over the last four quarters, ...